MRNA vs MRVL

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 08, 2026

MRNA

36.5
AI Score
VS
MRNA Wins

MRVL

35.7
AI Score

Investment Advisor Scores

MRNA

37score
Recommendation
AVOID NEW MONEY

MRVL

36score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric MRNA MRVL Winner
Forward P/E 23.0415 62.1118 MRNA
PEG Ratio 0 1.3866 Tie
Revenue Growth 2.1% 36.5% MRVL
Earnings Growth -85.1% 50.0% MRVL
Tradestie Score 36.5/100 35.7/100 MRNA
Profit Margin -141.4% 27.9% MRVL
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY AVOID NEW MONEY Tie

Relative Price Performance (Last 90 Days)

MRNA 1M: +45.3% · 3M: +188.6% MRVL 1M: +16.9% · 3M: +16.5%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (50.6% over 20 days), RSI 64

RSI (14): 63.8 · Price: $197.00

MRVL

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (7.9% over 20 days), RSI 61

RSI (14): 60.9 · Price: $274.66

Fundamentals Snapshot

Metric MRNA MRVL
Market Cap — —
Forward P/E -41.1 81.0
Trailing P/E — 94.3
Revenue (TTM) — —
Revenue Growth 0.0% 0.4%
Gross Margin -0.7% 0.5%
Operating Margin -5.6% 0.2%
EPS -7.98 3.02
Dividend Yield — 0.00%

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.